Roger Bruggermann MSc,PharmD, PhD

Dr. Bruggermann is currently working at Radboud University Nijmegen Medical Centre. He has received MSc, PharmD, PhD degrees from University of Utrecht, Radboud University Medical Center. He is specialized in Clinical Research, Clinical pharmacology, Infectious Disease, Pharmacokinetics, ToxicologyResearch.

Roger has been responsible for the translational pharmacological research on anti-infectives, specifically antifungal drugs. His work involves three domains ranging from in vitro and animal research to trials in humans with strong national and international collaborations. Roger's research involves the resolution of PK and PD behavior and factors that impact this. A major focus has been on the application of TDM in specific cohorts of patients. He has experience in the design, conduct, analysis and reporting of single and multi-centre trials involving azole and echinocandin drugs in a wide variety of patients such as (pediatric) hematology and intensive care unit patients and healthy volunteers trials.

Roger is a member of a number of national and international societies including the "European Society for Clinical Microbiology and Infectious Diseases (ESCMID)"; the ESCMID PK/PD Study Group and the ESCMID Fungal Infections Study Group; the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and the "Anti-infective Committee of the IATDMCT"; the International Society of Anti-infective Pharmacology (ISAP) ; the Dutch Society for Hospital Pharmacist (NVZA) and the Special Interest Group for Infectious Diseases of the NVZA. Furthermore Roger is actively involved in the writing of international guidelines on the management of invasive fungal infections (ECIL and ESCMID) and the organisation of international courses on PK-PD of antifungal drugs.